World Neurosurg:比较罗哌卡因止血明胶海绵和生理盐水对脊柱内固定手术患者术后疼痛的影响:一项随机临床试验

2019-08-31 anesthGH 罂粟花

目前,对于脊柱手术患者术后疼痛的控制尚无确切方案。本研究旨在比较应用含罗哌卡因可吸收明胶海绵和生理盐水对行脊柱内固定术患者术后疼痛的影响。

背景与目的

目前,对于脊柱手术患者术后疼痛的控制尚无确切方案。本研究旨在比较应用含罗哌卡因可吸收明胶海绵和生理盐水对行脊柱内固定术患者术后疼痛的影响。

方  法

本次前瞻性双盲随机对照试验共纳入30例脊柱手术患者。在手术结束时,由外科医生将含有0.5%罗哌卡因或0.9%生理盐水的止血明胶海绵涂抹在患者手术椎体的横突上。 在两组(罗哌卡因与生理盐水)术后48小时内,每4小时使用视觉模拟评分(VAS)评估患者疼痛程度。同时记录术后阿片类药物的总使用量。

结 果

术后48小时,接受局部麻醉药浸泡的止血明胶海绵患者的VAS评分显着低于接受生理盐水浸泡的明胶海绵患者。此外,接受局部麻醉药浸泡的止血明胶海绵患者术后48h内阿片类药物的平均总消耗量(53.5±51.0 mg)也明显低于使用生理盐水浸泡止血明胶海绵的患者(140.5±102mg),差异有统计学意义(P<0.05)。

结 论

术中,罗哌卡因止血海绵在手术椎骨横突中的应用,可减少腰椎内固定手术患者的术后疼痛,表现为VAS评分和阿片类药物总剂量的降低。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1661387, encodeId=258c166138e66, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Thu Apr 02 01:55:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859646, encodeId=216b1859646ae, content=<a href='/topic/show?id=fecf69541dd' target=_blank style='color:#2F92EE;'>#生理盐水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69541, encryptionId=fecf69541dd, topicName=生理盐水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Tue Oct 29 19:55:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263077, encodeId=3ec712630e7eb, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364521, encodeId=1ad71364521c6, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512572, encodeId=537f15125e227, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546711, encodeId=00451546e1160, content=<a href='/topic/show?id=2230303e266' target=_blank style='color:#2F92EE;'>#内固定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30372, encryptionId=2230303e266, topicName=内固定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4faa13929419, createdName=41514491@qq.com, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1661387, encodeId=258c166138e66, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Thu Apr 02 01:55:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859646, encodeId=216b1859646ae, content=<a href='/topic/show?id=fecf69541dd' target=_blank style='color:#2F92EE;'>#生理盐水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69541, encryptionId=fecf69541dd, topicName=生理盐水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Tue Oct 29 19:55:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263077, encodeId=3ec712630e7eb, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364521, encodeId=1ad71364521c6, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512572, encodeId=537f15125e227, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546711, encodeId=00451546e1160, content=<a href='/topic/show?id=2230303e266' target=_blank style='color:#2F92EE;'>#内固定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30372, encryptionId=2230303e266, topicName=内固定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4faa13929419, createdName=41514491@qq.com, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1661387, encodeId=258c166138e66, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Thu Apr 02 01:55:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859646, encodeId=216b1859646ae, content=<a href='/topic/show?id=fecf69541dd' target=_blank style='color:#2F92EE;'>#生理盐水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69541, encryptionId=fecf69541dd, topicName=生理盐水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Tue Oct 29 19:55:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263077, encodeId=3ec712630e7eb, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364521, encodeId=1ad71364521c6, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512572, encodeId=537f15125e227, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546711, encodeId=00451546e1160, content=<a href='/topic/show?id=2230303e266' target=_blank style='color:#2F92EE;'>#内固定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30372, encryptionId=2230303e266, topicName=内固定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4faa13929419, createdName=41514491@qq.com, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=)]
    2019-09-02 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1661387, encodeId=258c166138e66, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Thu Apr 02 01:55:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859646, encodeId=216b1859646ae, content=<a href='/topic/show?id=fecf69541dd' target=_blank style='color:#2F92EE;'>#生理盐水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69541, encryptionId=fecf69541dd, topicName=生理盐水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Tue Oct 29 19:55:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263077, encodeId=3ec712630e7eb, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364521, encodeId=1ad71364521c6, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512572, encodeId=537f15125e227, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546711, encodeId=00451546e1160, content=<a href='/topic/show?id=2230303e266' target=_blank style='color:#2F92EE;'>#内固定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30372, encryptionId=2230303e266, topicName=内固定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4faa13929419, createdName=41514491@qq.com, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=)]
    2019-09-02 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1661387, encodeId=258c166138e66, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Thu Apr 02 01:55:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859646, encodeId=216b1859646ae, content=<a href='/topic/show?id=fecf69541dd' target=_blank style='color:#2F92EE;'>#生理盐水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69541, encryptionId=fecf69541dd, topicName=生理盐水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Tue Oct 29 19:55:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263077, encodeId=3ec712630e7eb, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364521, encodeId=1ad71364521c6, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512572, encodeId=537f15125e227, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546711, encodeId=00451546e1160, content=<a href='/topic/show?id=2230303e266' target=_blank style='color:#2F92EE;'>#内固定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30372, encryptionId=2230303e266, topicName=内固定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4faa13929419, createdName=41514491@qq.com, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1661387, encodeId=258c166138e66, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Thu Apr 02 01:55:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859646, encodeId=216b1859646ae, content=<a href='/topic/show?id=fecf69541dd' target=_blank style='color:#2F92EE;'>#生理盐水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69541, encryptionId=fecf69541dd, topicName=生理盐水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Tue Oct 29 19:55:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263077, encodeId=3ec712630e7eb, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364521, encodeId=1ad71364521c6, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512572, encodeId=537f15125e227, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546711, encodeId=00451546e1160, content=<a href='/topic/show?id=2230303e266' target=_blank style='color:#2F92EE;'>#内固定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30372, encryptionId=2230303e266, topicName=内固定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4faa13929419, createdName=41514491@qq.com, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=)]

相关资讯

Anesthesiology:胸段硬膜外麻醉中罗哌卡因与布比卡因分别对下尿路功能的影响:随机临床实验

使用罗哌卡因与布比卡因相比,在胸段硬膜外镇痛法中使用罗哌卡因可以显著降低排尿后残余,对逼尿肌功能损害更小。

Medicine :臂丛神经阻滞,左布比卡因和罗哌卡因的术后镇痛效果并无差异

在药物的基础上,一般认为左布比卡因较罗哌卡因可持续更长的时间。然而,大多数报告臂丛阻滞时这两种麻醉剂在镇痛效果上并未存在明显的差异。本研究旨在对比左布比卡因和罗哌卡因用于治疗超声引导下臂丛神经阻滞术后的镇痛效果。 研究共纳入62名接受骨科手术的患者,随机接受左布比卡因( L组、n = 31)或罗哌卡因(R组,n = 31  )。记录患者术后镇痛持续时间、运动阻滞偏移时间、术后镇痛药用量及术后

Anesth Analg:持续性罗哌卡因切口局部浸润与鞘内注射吗啡在剖宫产后镇痛效果中的比较:前瞻性、随机对照、双盲试验

剖宫产后,术后疼痛管理可以促进早期康复,有助于预防产后抑郁症和慢性疼痛。目前的前瞻性、随机对照、双盲研究评估了剖宫产分娩后鞘内镇痛和连续罗哌卡因伤口浸润的持续时间和作用。主要结局是镇痛持续时间,其定义为首次增加使用吗啡的时间。次要结局是术后吗啡的累积用量,不需使用吗啡的患者数量,不良反应的发生率和首次下床活动的时间。

Anesthesiology:胸段硬膜外镇痛对下尿路功能的影响:罗哌卡因与布比卡因的比较

布比卡因胸段硬膜外镇痛可导致临床相关的由于逼尿肌松弛而引起的尿液残留。本研究通过评估尿液残留量和最大流量速率,从而比较使用罗哌卡因与布比卡因对膀胱功能障碍的影响程度。我们的假设为罗哌卡因会导致较低水平的尿液残留,由于已证明罗哌卡因对运动神经阻滞的作用较小。

Brit J Ophthal:上海九院汪朝阳教授发现玻璃体切割术间使用罗哌卡因疼痛和出血风险更低

为了比较1%罗哌卡因(Ropivacaine), 0.75%布比卡因(Bupivacaine), 2%利多卡因以及0.75%丁哌卡因和2%利多卡因(bupi+lido)的混合制剂在玻璃体切除术球周麻醉的术中和术后临床特性。中国上海交通大学附属第九人民医院汪朝阳教授和新华医院的研究人员开展了一项前瞻性随机双盲临床研究。该研究于2月7日在 British Journal of Ophthal

Medicine:罗哌卡因联合右美托咪定用于骶管麻醉对痔切除术患者的镇痛作用的影响:前瞻性随机对照试验

右美托咪定作为罗哌卡因的辅助用药,延长了骶管阻滞的持续时间,改善了术后镇痛,且其对接受痔切除术的成年患者没有明显的副作用。